重组人脑利钠肽对急性重症心力衰竭患者治疗效果及预后的影响

Effect of Recombinant Human Brain Natriuretic Peptide on the Treatment Effect and Prognosis in Patients with Acute Severe Heart Failure

目的将重组人脑利钠肽用于急性重症心力衰竭患者中,评价治疗效果和对预后的影响。方法 2015年5月—2017年7月该院纳入治疗的80例急性重症心力衰竭患者看成该文资料,参考治疗方法不同分组,每组收入40例,实验组行重组人脑利钠肽治疗,参照组行异舒吉治疗,统计两组相关指标。结果实验组气促缓解用时(13.9±2.0)h、住院天数(9.0±1.2)d、治疗后的左室射血分数值(49.0±7.2)%、治疗后的N末端B型利钠肽原测定值(2 876.6±1 324.0)pg/mL对比参照组(27.0±5.0)h、(12.3±2.0)d、(43.0±6.4)%、(4 758.0±1 614.5)pg/mL,差异有统计学意义(t=15.385 1、8.948 3、3.939 1、5.698 8,P=0.000 0、0.000 0、0.000 2、0.000 0<0.05),实验组不良心血管事件合计率5.00%对比参照组22.50%,差异有统计学意义(χ~2=5.164 7,P=0.023 1<0.05)。结论急性重症心力衰竭患者采用重组人脑利钠肽治疗展示较优治疗效果,能有效改善预后。

Objective The recombinant human brain natriuretic peptide was used in patients with acute severe heart failure to evaluate the effect of treatment and its influence on the prognosis. Methods From May 2015 to July 2017, 80 cases of acute severe heart failure patients treated in this hospital were selected, and they were grouped according to treatment methods, each group of 40 cases. The ex-perimental group received recombinant human brain natriuretic peptide therapy. The control group was treated with Isogiz therapy,and two groups of related indicators were counted. Results The time required for airway remission in the experimental group was（13.9±2.0）h, the length of hospital stay（9.0±1.2）d, the value of left ventricular ejection fraction after treatment（49.0 ±7.2）%, and the Nterminal B-type natriuretic peptide assay after treatment of（2 876.6 ±1 324.0）pg/mL and those in the control group of（27.0 ±5.0）h,（12.3±2.0）d,（43.0±6.4）%,（4 758.0±1 614.5）pg/mL, the difference was statistically significant（t=15.385 1, 8.948 3, 3.939 1, 5.698 8,P =0.000 0, 0.000 0, 0.000 2,0.000 0 0.05）. The total rate of adverse cardiovascular events in the experimental group was 5.00%compared with the control group 22.50%. the difference was statistically significant（χ^2=5.164 7, P=0.023 10.05）. Conclusion The use of recombinant human brain natriuretic peptide in patients with acute severe heart failure shows superior therapeutic effect and can effectively improve the prognosis.